Video

Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Patients who have NETs are generally more benign cases, making it important to treat them differently, states Comperat. There are patients who will metastasize, so it is crucial for the pathologist to make the right diagnosis and for the medical oncologist to understand how to best treat these patients.

There are new data about the molecular biology of the tumor. There are 2 subgroups of NETs, one of which is more genetically unstable. Having different strategies for these tumors will benefit the patients, explains Comperat.

Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Sumanta Kumar Pal, MD, FASCO,
Kohei Shitara, MD